- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01407068
Administration of Two Injections for Multiple Dupuytren's Contractures
An Open-label Study to Assess the Safety and Efficacy of Concurrent Administration of Two Injections of AA4500 0.58 mg Into the Same Hand of Subjects With Multiple Dupuytren's Contractures
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Methodology/Study Design:
This is an open-label, study in men and women with multiple Dupuytren's contractures. Approximately 60 subjects who have at least two Dupuytren's contractures caused by palpable cords in the same hand will be enrolled.
After all pre-injection procedures are completed on Day 1, eligible men and women will receive two concurrent injections of AA4500 0.58 mg into the same hand. On Day 2, a finger extension procedure to facilitate cord disruption will be performed in those subjects who do not have spontaneous disruption of their cord(s). Follow-up visits for the evaluation of safety and efficacy will be on Day 8, Day 30, and Day 60.
Upon completion of the Day 60 follow-up visit, subjects who require further treatment will have the option to receive three additional open-label treatments according to the XIAFLEX package insert (Appendix C). Subjects may receive up to a total of five injections and individual cords may receive up to a total of three injections.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Auchenflower, Australia, QLD 4067
- Austrials
-
Auchenflower, Australia, QLD4066
- Austrials
-
Kippa Ring, Australia, QLD 4020
- Austrials
-
Malvern, Australia, VIC 3144
- Emeritus Research
-
-
-
-
Arizona
-
Tucson, Arizona, United States, 85712
- Tucson Orthopaedic Institute
-
-
Indiana
-
Indianapolis, Indiana, United States, 46260
- The Indiana Hand Center
-
-
New York
-
Stony Brook, New York, United States, 11794
- Department of Orthopaedics SUNY-Stony Brook
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73109
- Health Research Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provide written informed consent
- Be a man or woman ≥ 18 years of age
- Have a diagnosis of Dupuytren's disease and have at least 2 fixed-flexion contractures on the same hand that are ≥ 20º in PIP and/or MP joints in fingers, other than the thumbs, which are caused by palpable cords suitable for treatment
- Have a positive "table top test" defined as the inability to simultaneously place the affected finger(s) and palm flat against a table top
- Either be using an accepted method of birth control (ie, surgical sterilization; intra uterine contraceptive device; oral contraceptive; diaphragm or condom in combination with contraceptive cream, or jelly or foam) and have negative pregnancy testing before administration of AA4500, if a female of childbearing potential, or be a postmenopausal female (no menses for at least 1 year or hysterectomy)
- Not have any clinically significant medical history or condition(s) that would, in the opinion of the investigator, substantially increase the risk associated with the subject's participation in the protocol or compromise the scientific objectives of the study
- Be able to comply with the study visit schedule as specified in the protocol
Exclusion Criteria:
- Received surgery (fasciectomy or surgical fasciotomy) and/or needle aponeurotomy/fasciotomy on the selected joints to be treated within 90 days before the first injection of AA4500
- Has a chronic muscular, neurological, or neuromuscular disorder that affects the hands
- Has a known systemic allergy to collagenase or any other excipient of AA4500
- Has received any collagenase treatments (eg, Santyl® ointment and/or XIAFLEX/XIAPEX) within 30 days before injection of AA4500
- Is currently receiving or plans to receive anticoagulant medication or has received anticoagulant medication (except for ≤ 150 mg aspirin daily and over-the-counter nonsteroidal anti-inflammatory drugs [NSAIDs]) within 7 days before injection of AA4500)
- Has a known recent history of stroke, bleeding, or other medical condition, which in the investigator's opinion would make the subject unsuitable for enrollment in the study
- Is known to be immunocompromised or human immunodeficiency virus (HIV) positive
- Has a history of illicit drug abuse or alcoholism within the year before injection of AA4500
- Received an investigational drug within 30 days before injection of AA4500
- Is a pregnant or lactating female
- Has any clinically significant medical history or condition(s), including conditions that affect the hands, that would, in the opinion of the investigator, substantially increase the risk associated with the subject's participation in the protocol or compromise the scientific objectives of the study
- Has jewelry on the hand to be treated that cannot be removed
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: AA4500
AA4500 collagenase clostridium histolyticum
|
2 concurrent injections (0.58 mg) into 2 cords on the same hand
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change From Baseline in Total Fixed Flexion
Time Frame: 30 days after last injection
|
Total fixed flexion is defined as the sum of the fixed flexion contractures of the two joints receiving treatment.
Change in fixed-flexion contracture is measured in degrees where a decrease of 100% would correspond to a reduction in contracture to 0 degrees
|
30 days after last injection
|
Change in Total Range of Motion
Time Frame: 30 days after last injection
|
The total range of motion is the sum of the range of motion measurements of the two treated joints.
Range of motion is defined as difference between full flexion angle and full extension angle expressed in degrees.
|
30 days after last injection
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subject Satisfaction With Treatment
Time Frame: 60 days after last injection
|
At the Day 60 follow-up visit, each subject will be asked to rate his/her satisfaction with treatment as follows:
|
60 days after last injection
|
Investigator Assessment of Improvement With Treatment
Time Frame: 60 days after last injection
|
At the Day 60 follow-up visit, the investigator will determine the degree of improvement in the severity of the subject's treated finger(s) compared with screening as follows:
|
60 days after last injection
|
Clinical Success by Joint Type
Time Frame: 30 days after injection
|
Clinical success is defined as a reduction in fixed flexion contracture to 5° or less 30 days after injection of AA4500.
|
30 days after injection
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AUX-CC-864
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dupuytren's Contracture
-
University of MinnesotaRecruitingDupuytren Contracture | Dupuytren Disease of Finger | Dupuytren's Disease | Dupuytren Disease of Palm and Finger | Dupuytrens Contracture of Both Hands | Dupuytren's Disease of Palm of Right Hand | Dupuytren's Disease of Palm of Left Hand | Dupuytren Contracture of Right Palm | Dupuytren Contracture... and other conditionsUnited States
-
Catherine Vandepitte, M.D.Pacira Pharmaceuticals, IncCompletedDupuytren's Contracture of the Hand (Viking's Disease)Belgium
-
Uppsala UniversityRecruitingDupuytren Contracture | Dupuytren's DiseaseSweden
-
Hospital for Special Surgery, New YorkAuxilium Pharmaceuticals, Inc.CompletedDupuytren's DiseaseUnited States
-
Indiana Hand to Shoulder CenterStony Brook UniversityTerminatedDupuytren's DiseaseUnited States
-
Foundation for Orthopaedic Research and EducationEndoPharmceuticalsActive, not recruitingDupuytren Contracture | Dupuytren's DiseaseUnited States
-
Theresa Bass-GoldmanEndo PharmaceuticalsCompleted
-
Technische Universität DresdenPfizer; GWT-TUD GmbHCompleted
-
Massachusetts General HospitalCompleted
-
Regionshospitalet SilkeborgRecruitingNeoplasms | Neoplasms, Connective and Soft Tissue | Neoplasms by Histologic Type | Joint Diseases | Musculoskeletal Diseases | Connective Tissue Diseases | Neoplasms, Connective Tissue | Fibroma | Contracture | Dupuytren Contracture | Dupuytren's Disease | Neoplasm, Fibrous TissueDenmark
Clinical Trials on AA4500 collagenase clostridium histolyticum
-
Endo PharmaceuticalsCompletedAdvanced Dupuytren's DiseaseAustralia
-
Endo PharmaceuticalsCompletedDupuytren's DiseaseUnited States, Australia
-
Endo PharmaceuticalsCompletedA Pharmacokinetic Study of AA4500 (XIAFLEX™, Proposed Name) in Subjects With Dupuytren's ContractureDupuytren's ContractureUnited States
-
Endo PharmaceuticalsCompletedDupuytren's DiseaseUnited States, Australia, Sweden, United Kingdom
-
Endo PharmaceuticalsCompletedAdvanced Dupuytren's DiseaseUnited States
-
Gerut, Zachary, M.D.Advance Biofactures CorporationCompleted
-
Stony Brook UniversityEndo Pharmaceuticals; Biospecifics Technologies Corp.Completed
-
Endo PharmaceuticalsCompletedDupuytren's ContractureUnited States
-
Endo PharmaceuticalsCompletedAdhesive Capsulitis | Frozen ShoulderUnited States, Australia
-
Endo PharmaceuticalsCompletedDupuytren's ContractureUnited States